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Title: PEPtalk2: Results of a pilot randomised controlled trial to compare VZIG and aciclovir as post-
exposure prophylaxis (PEP) against chickenpox in children with cancer 
 
Abstract 
Objective: To determine the likely rate of patient randomisation and to facilitate sample size 
calculation for a full-scale Phase III trial of VZIG and acyclovir as post-exposure prophylaxis against 
chickenpox in children with cancer 
Design: Multi-centre pilot randomised controlled trial of varicella zoster immunoglobulin (VZIG) and 
oral aciclovir 
Setting: England, UK 
Patients: Children under 16 years of age with a diagnosis of cancer: currently or within 6 months of 
receiving cancer treatment and with negative varicella zoster virus (VZV) serostatus at diagnosis or 
within the last 3 months.  
Interventions: Study participants who have a significant VZV exposure were randomised to receive 
PEP in the form of VZIG or aciclovir after the exposure 
Main outcome measures: Number of patients registered and randomised within 12 months of the 
trial opening to recruitment and incidence of break-through varicella  
Results: The study opened in 6 sites over a 13 month period. 482 patients were screened for 
eligibility, 32 patients were registered and 3 patients were randomised following VZV exposure. All 3 
were randomised to receive aciclovir and there were no cases of break-through varicella.  
Conclusions: Given the limited recruitment to the PEPtalk2 pilot, it is unlikely that the necessary 
sample size would be achievable using this strategy in a full-scale trial. The study identified factors 
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that could be used to modify the design of a definitive trial but other options for defining the best 
means to protect such children against VZV should be explored.  
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Background 
Of the approximate 1500 children newly diagnosed with cancer annually in the UK and the Republic 
of Ireland, almost 25% lack immunity to varicella zoster virus (VZV), the cause of chickenpox and 
shingles (1). Treatment-related immunosuppression and for certain cancer types, the disease itself 
place these individuals at high risk of severe infection. In healthy children, primary VZV infection 
usually follows a benign clinical course and significant complications are uncommon (2). By contrast, 
infection in immunocompromised patients can result in treatment delays, significant morbidity and 
even mortality (3-7). 
 
Current guidelines for this group of patients emphasise the importance of minimizing their contact 
with VZV, and of providing post-exposure prophylaxis (PEP) should this occur. A report on use of PEP 
in children with cancer in the UK and Republic of Ireland suggested that PEP is delivered to 
approximately 250 children with cancer annually (1). However, there is a striking lack of consensus 
on which PEP is best for this group. The gold standard has been an injection of varicella zoster 
immune globulin (VZIG) to be given as soon as possible after exposure. VZIG is prepared from pooled 
plasma of donors with suitably high titres of VZV IgG antibody. The use of VZIG is supported by 
evidence from historical studies (3, 8-10).  However, there is a widely reported range of efficacy of 
VZIG, depending on exposure and level of immunosuppression (10, 11). VZIG is associated with 
injection discomfort, inconvenience and significant cost. Furthermore, due to a theoretical risk of 
transmission of variant Creutzfeldt-Jakob disease  (vCJD) from plasma products, VZIG used in the UK 
is now prepared from plasma sourced from outside the UK, and its supply is limited by the 
availability of suitable donors (12). Lack of suitable donors may intensify as varicella-immunised 
individuals begin to enter adulthood in the USA and other countries which currently are the source 
of the VZIG used in the UK.   
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Aciclovir, an oral antiviral drug that is effective in the treatment of VZV and herpes simplex virus 
(HSV) disease, has been used as an alternative means of PEP in some UK paediatric oncology centres 
for over twenty years (1, 13). A national guideline of the Royal College of Paediatrics and Child 
Health (RCPCH) published in 2002, proposed VZIG and aciclovir as equivalent alternatives as PEP in 
this patient group (14). However, Public Health England’s Green Book publication on varicella, 
updated in 2015, recommends only VZIG as PEP for immunocompromised children and does not 
include aciclovir as an alternative (12). Small observational studies in healthy children have reported 
varicella rates of 0-77% after using aciclovir as PEP (15-17).  In immunocompromised children, a few 
small retrospective studies describe no breakthrough varicella infections following aciclovir as PEP 
while others report a rate of 3-22% (18-23).  
 
To date, no randomised trials have compared the efficacy of VZIG and aciclovir as PEP in 
immunocompromised patients. The PEPtalk feasibility study reported that varicella exposures are 
frequent but that the approach to PEP in paediatric cancer patients is highly polarised among 
centres (1). Patients are given VZIG or aciclovir in approximately equal measure. Opinion is strongly 
polarised among UK paediatric oncologists who prescribe PEP on the basis of unit policy and 
experience and not necessarily patient preference. Furthermore, there are systematic differences in 
practice surrounding the delivery of PEP among centres using VZIG compared with aciclovir (such as 
definitions of exposure and policies concerning the re-checking of serology prior to administration of 
PEP). These considerations suggest that only a well-powered randomised controlled trial could 
provide evidence of a quality sufficient to support a change in practice. The main objective of this 
pilot study was therefore to determine the likely rate of patient recruitment and randomisation and 
to facilitate sample size calculation, in order to inform the design of a larger trial. 
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Methods: 
This pilot study was a UK-based multi-centre randomised controlled trial between VZIG and oral 
aciclovir as  PEP  in children with cancer. Study participants were recruited over a 13-month period 
from May 2014 until June 2015 from 6 hospitals.  
 
 
Study eligibility: 
 
The study was open to all children under 16 years of age with a diagnosis of cancer who were either 
receiving or within 6 months of receiving immunosuppressive treatment for cancer. Children who 
had a current or previous allogeneic or autologous haemopoietic stem cell transplant were excluded 
from the study. To be eligible for the study, children were required to be VZV seronegative at the 
time of diagnosis or within the previous 3 months.  
 
 
Study design: 
VZV seronegative children were randomised to receive either VZIG or aciclovir following a significant 
exposure to varicella. The definition of significant exposure included any household exposure,  non-
household exposure by means of: contact in the same room, e.g. in a classroom or a two-to four-bed 
hospital bay, for 15 minutes or more or face-to-face contact, e.g. while having a conversation (12). 
Registration and randomisation were carried out by telephone by the Cancer Research Clinical Trials 
Unit, University of Birmingham. Patients were randomised using simple randomisation with a 
restriction to state that if an imbalance of greater than 2 should occur the next patient would be 
allocated to the smaller of the treatment arms. 
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Consent: 
As PEPtalk2 had a two-stage enrolment process, beginning with registration and then followed (in 
the event of a chickenpox exposure) by randomisation, written informed consent from the patient’s 
legal representative was obtained at both stages. 
 
 
Study procedures: 
Blood for VZV serology was taken at the time of exposure and at 12 weeks (+/- 2 weeks) following 
exposure. Patients and their families were given a PEPtalk2 Treatment Diary (including both trial-
specific questions and a standardised EuroQol EQ-5D questionnaire) to record their experiences and 
to collect information about the impact on quality of life.  Clinicians involved in caring for children 
participating in the trial were sent a survey to obtain their views on the randomisation process and 
the trial in general. 
 
 
Outcome measures: 
The primary outcome measure was the number of patients randomised within 12 months of the trial 
opening to recruitment. Considered in relation to the number of patients registered and the number 
of patients screened, this would allow an informed evaluation of the trial enrolment rate amongst 
eligible patients. 
 
Secondary outcome measures included seroconversion rates, incidence of break-through varicella, 
quality of life assessments, clinicians’ views and cost effectiveness.  All analysis conducted was 
descriptive. For continuous data means with standard deviations or medians with interquartile 
ranges are presented, while for binary data the number and percentage are reported.  
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Results: 
 
A total of 482 patients were screened for eligibility from 6 centres over the study period. Of these, 
32 patients were registered and 3 patients were randomised following VZV exposure. All 3 were 
randomised to receive aciclovir. All 3 were seronegative at 12 weeks post exposure and there were 
no break-through varicella infections.  
 
Figure 1: Consort diagram 
 
 
 
 
 
A consistent proportion of patients were not eligible for registration because they were seropositive 
(ranging from 65-70% by month, overall 70%). Those with indeterminate results were also not 
eligible for registration and this proportion declined over the first 6 months of the course of the trial, 
from 20% to 13%, and then remained steady at 11-13% for the remainder of the trial (overall 12.3%).  
The proportion of patients that were seronegative and therefore eligible for participation (n=76, 
16%) was also consistent over the study period (12% for the first month and then 14-17% by month). 
Seronegativity status varied by age: 50% in 2-4 year olds, 21.1% in 5-7 year olds,  5.3% in 8-10 year 
olds and 7.9% in >10 years of age. The median age of seronegative patients was 3.8 years.  
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Figure 1 also shows the reasons for declining to be registered (n=44, 57.9%). The major reason given 
was the distance of travel to the trial site (n=23, 52%). The other main reasons were the need for 
additional oral medication (n=6, 14%) and the need for additional blood samples (n=8, 18%). 
Personal communications with local staff indicated that families who declined due to the need for 
further oral medication did so as the patient(s) did not have nasogastric tubes anymore and had 
struggled with oral medications previously, or that the patient was back at school and taking oral 
medications during school time was an issue for them.  
 
 
 
 
 
 
 
Outcome measures  
 
Three patients were randomised to receive PEP (9% of registered patients).  The age of the 3 
patients was 5.8, 6.1 and 6.8 years. For two patients, the source of contact was a sibling and in the 
other it was a source outside the household. The 3 were all randomised to receive aciclovir and all 3 
were assessed as being compliant with the full course. No patient withdrawals were reported and no 
patients were found to be ineligible post randomisation. There were no cases of  varicella among the 
patients and none seroconverted between exposure and the 12 week follow-up. Cost effectiveness 
analysis could not be conducted as there were no events in the VZIG arm. As no hospital admissions 
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were reported no cost effectiveness could be calculated.  No adverse events, serious adverse events 
or deaths were reported in the trial. Quality of life questionnaires were returned for all 3 
randomised patients (complete data for 2).  
 
 
 
 
 
Clinician surveys  
 
Feedback was recorded from all participating clinicians (n=8). Specific feedback included that the 
patient information sheet could be condensed further, that the effort taken in registering patients 
should be recognised in terms of portfolio accruals, that shared care centre involvement was 
important, and that routine practice currently does not require serological screening of patients with 
a history of VZV contact.  
 
 
Discussion: 
 
The main objective of this pilot study was to determine the likely rate of patient randomisation and 
to facilitate sample size calculation, in order to inform the design of a larger trial addressing the 
issues around post exposure prophylaxis in this population (24). It was estimated that if, for 
example, the pilot study was successful in recruiting 50 patients from up to seven UK centres over a 
12-month period, then a larger trial that recruited from twice as many centres over a 24-month 
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period was realistic and could recruit around 200 patients. This was seen as achievable in a UK 
network. If found to be necessary the trial size could also be increased further, but an international 
consortium would then likely be required to achieve this.  This main objective was therefore 
achieved.  
 
The finding that the pilot study randomised only 3 patients from 6 centres over a 13-month study 
period indicates that recruitment of sufficient numbers to a definitive and similarly designed trial 
would not be achievable. As intended, the pilot study has allowed us to identify a number of reasons 
for this low rate of recruitment and indeed, with this knowledge, a number of these could now be 
avoided in the design of a further trial - but nevertheless, a different approach to addressing the 
issues around PEP will likely be needed.  This study revealed a lower probability of being 
seronegative among trial participants than expected.  Undertaking this pilot study was more efficient 
than attempting a large definitive trial which would have failed to achieve its recruitment targets 
and wasted money, time, and the voluntary efforts of the families involved. It is difficult to interpret 
the value of QOL scores from only 3 patients (complete data for 2) but this will be important to 
consider in future trial planning.  
 
Only 6, rather than 7, sites were able to participate in the pilot study and of these only 2 were able 
to participate for the full trial period. Choice of sites might be critical as one site dominated in terms 
of registration (15/32). 
 
An important eligibility criterion was omitted from the original protocol i.e. being up to 6 months 
post cancer treatment. This was introduced as a later amendment and may have had some impact 
(likely small) on the recruitment rate. Furthermore, it would be important to include haematopoietic 
stem cell transplant recipients in future studies as prophylactic regimens to prevent VZV infection in 
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this group are also controversial and vary widely (25). This group was excluded from the pilot study 
design due to low projected patient numbers in the study centres, heterogeneity of conditioning 
regimes and underlying diagnoses and variation in the use of prophylactic aciclovir in these patients.  
 
The rate of seronegativity (16%) found in this study was lower than predicted (24%) (1). An 
important factor here was the high rate of indeterminate results (around 13%). Not to have 
incorporated this eventuality in the protocol was an important omission as in practice such cases 
should be considered as potentially susceptible and therefore recommended to receive post-
exposure prophylaxis.  Additionally, it was not routine practice to reassess status in those with a 
history of VZV or who are found to be VZV seropositive at diagnosis. This should also have been 
addressed in the protocol and repeat serology obtained on such children. This may have increased 
the number of potentially eligible children for registration. We and others have shown that children 
can lose their immunity over the course of treatment and become seronegative (26-28). 
 
The reasons given for not agreeing to participate are important and this knowledge would allow 
adjustments to be made to future trials. For example, it would be important to ensure that all 
hospitals (shared care sites) that fall into the recruitment areas of major sites are engaged in the 
study so that travel for patients is minimised.  
 
Concern was evident regarding the need for blood samples and these could be reduced in a future 
trial, for example the need to repeat serology again at randomisation.  Furthermore, testing of oral 
fluids may be a more acceptable way of ascertaining serology, rather than blood samples in the 
future (29).  
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During the trial period there was a lower rate of VZV exposure (10%) than originally predicted (20%). 
Although accurate data on the rates of VZV exposure and disease are not available for UK children 
with malignancy, a 20-30% risk of varicella exposure during a child’s mean 2.5 years of maintenance 
therapy for ALL has been calculated. (30) In another study of 86 children followed through the 
duration of ALL treatment there were 26 episodes of  varicella and herpes zoster, of which 17 
occurred during maintenance therapy. (31) There is also some indication that exposure of the 
general population during this time period was also lower than in other years. Clearly, had we 
identified susceptible children earlier in the trial period and then followed them for a longer period 
of time (as could be done in a definitive trial), there would have been greater exposure to VZV and 
this would have minimized the impact of seasonal variations in VZV exposure. 
 
This pilot study suggests that it will likely be too challenging to undertake a definitive, non-inferiority 
trial of these 2 forms of PEP in a UK-only study. In the original considerations around the trial, and 
assuming a relatively large non-inferiority margin of 10%, it was estimated that about 450 patients 
would be needed with a one-sided alpha of 0.05 and 80% power; if the alpha were to be relaxed the 
number would be reduced (with alpha=0.1, n=350; alpha=0.15, n=280; alpha=0.2, n=240). A smaller 
trial might however, be considered to be reasonable as two standard treatments are being 
compared, as opposed to comparing a standard treatment with a novel agent. 
 
Is a definitive randomised trial still required? In the UK, we do not have a routine varicella vaccine 
program in place, in contrast to a number of other industrialised countries. Such countries have seen 
a dramatic decline in the incidence of varicella in their childhood population in both their vaccinated 
and unvaccinated populations through herd immunity. VZV remains an issue in children with cancer 
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in all countries without routine immunisation programmes (32-34). The UK Joint Committee on 
Vaccination and Immunisation (JCVI) is currently reviewing the status of the VZV vaccine; even if 
introduced it’s impact on this population would not be felt for some time.  
 
The equipoise between aciclovir and VZIG as the best way of providing post exposure prophylaxis 
remains. No substantial data have been published in the interim that suggest one is superior to the 
other. One study only (published in Spanish), refers to the experience in one centre where both PEP 
options are available with no reported adverse effects in relation to the different prophylaxis 
measures nor any secondary cases observed at 30 days (19). When treating children with cancer, it is 
imperative to have reliable evidence rather than to depend on belief and it may be that some 
clinicians should reconsider their recommendation of PEP for patients.  
 
The lack of published evidence for the effectiveness of aciclovir represents a major barrier to 
informed decision-making. Historically, no prospective UK surveillance data have been collected to 
document the occurrence of varicella in relation to the mode of PEP whereas this may now be an 
appropriate methodology to pursue.  The implications of reaching consensus on whether aciclovir is 
at least equivalent to VZIG as post-exposure prophylaxis would reach well beyond UK paediatric 
oncology practice. 
 
Conclusions 
We conducted a pilot, randomised controlled trial of post varicella exposure prophylaxis in children 
with cancer, in order to determine the likely rate of randomisation and to facilitate sample size 
calculation for a definitive trial. Over a 13 month period we screened 482 children, registered 32 and 
randomised 3 children, from among 6 trial sites. A number of issues were identified that could be 
used to modify the design of a definitive trial but overall our experience suggests that the necessary 
Page 16 of 22
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
PEPtalk2 paper  Page 16 
 
sample size is not achievable using this recruitment strategy. Other options for defining the best 
means to protect such children against VZV should be explored. 
 
 
 
What is already known on this topic: 
• Chickenpox is a frequent and potentially serious risk for paediatric oncology patients 
• There is no consensus as to which type of post-exposure prophylaxis is best 
 
What this study adds: 
• A randomised controlled trial of VZIG and aciclovir is unlikely to be feasible in this patient 
population and a different approach will be required to address this issue 
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Figure 1: Consort Diagram  
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